Clinical Trial Update: Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Fluzoparib as adjuvant therapy for germline homologous recombination repair-mutated primary breast cancer; the Flamenco study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fluzoparib (fluzoparib)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING